Johnson & Johnson's Codman Neuro Recall Elevated To High Risk Class I

Published: Jan 23, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson subsidiary Codman Neuro's recall of its Trufill n-BCA liquid embolic system gets labeled as a Class I measure by the FDA. Codman Neuro, a division of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency's highest-risk classification. The Raynham, Mass.-based company develops devices for neurosurgery, neurovascular repair and neuromodulation.

Help employers find you! Check out all the jobs and post your resume.

Back to news